JAKARTA, Dec 16, 2025 - (ACN Newswire via SeaPRwire.com) - PT TASPEN (Persero), Indonesia's pension and social insurance administrator for civil servants and public officials, is strengthening its digital transformation efforts by launching a biometric-based monthly authentication system. This initiative aims to ensure accurate pension distribution while improving accessibility for millions of retirees across the country.The new system is integrated into Andal by TASPEN, a mobile application available on the App Store and Google Play Store. Using facial recognition technology, retirees can now verify their identity remotely with a simple selfie, eliminating the need to visit TASPEN branch offices or payment partners in person.As of October 2025, more than 1.63 million retired civil servants have successfully completed biometric authentication through Andal by TASPEN, indicating strong adoption and confidence in TASPEN's digital solutions. TASPEN Corporate Secretary Henra highlighted the initiative as a significant step toward modernizing public service delivery."Our Biometric Authentication feature reflects TASPEN's commitment to building a world-class digital service ecosystem. We want to ensure retirees can access their benefits safely and conveniently from anywhere," he said.Retired civil servants without prior biometric data can register directly through the app by scanning their national ID and completing guided facial verification. The system supports both claim and nonclaim services, offering greater flexibility and reducing administrative bottlenecks. Biometric authentication is required to ensure that pension benefits are delivered only to the rightful recipients, strengthening identity assurance and preventing fraud or impersonation. If participants do not complete the authentication, the system cannot validate their eligibility status, which may result in temporary withholding of monthly pension disbursement until verification is successfully completed.This initiative aligns with Indonesia's national agenda to enhance digital governance, streamline public services, and promote inclusive technology adoption. It also strengthens TASPEN's position at the regional level. TASPEN recently welcomed a benchmarking visit from Cambodia's National Social Assistance Fund (NSAF), which sought insights into TASPEN's digital pension management practices. Through continuous investment in digital innovation, TASPEN aims to establish itself as a leading reference for modern, secure, and efficient pension administration across Asia.PT TASPEN (Persero), formally referred to as the Civil Servants' Savings and Insurance Corporation, is an Indonesian state-owned enterprise mandated to administer old-age savings insurance and pension fund programs for State Civil Apparatus (ASN) and State Officials. Established on 17 April 1963, PT TASPEN (Persero) has consistently played a significant role in promoting social welfare and financial security for Indonesia's public sector workforce. At present, PT TASPEN (Persero) offers an array of products and services, including: Work Accident Security Program (Jaminan Kecelakaan Kerja/JKK), Death Security Program (Jaminan Kematian/JKM), Old-Age Savings Program (Tabungan Hari Tua/THT),and Pension Program.About PT TASPEN (Persero)PT TASPEN (Persero) currently serves as The First Chairman of the Asian Civil Service Pension Association (ACSPA), an association of civil service social security administrators in Asia, with members including Indonesia, South Korea, the Philippines, Thailand, and Cambodia. PT TASPEN (Persero) prioritizes participant convenience and security through the implementation of its digital super-app, Andal by TASPEN.For information, participants can contact the Call Center at 1500919, visit the official website www.taspen.co.id, tcare.taspen.co.id, or access all official social media channels of PT TASPEN (Persero). Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, December 16, 2025 - (ACN Newswire via SeaPRwire.com) – CTF Life and AlipayHK jointly announce a collaboration that makes CTF Life’s mobile application the first among Hong Kong life insurers* to enable premium payments via AlipayHK. This partnership streamlines the premium payment process, enhances service efficiency and elevates customer experience. With just one click, customers can settle premium payments without having to manually enter credit card or account details. This feature significantly reduces unnecessary steps, saves time and sets a new industry benchmark.In response to growing customer demand for a wider range of financial services, CTF Life will gradually enable AlipayHK as a payment option. This initiative fully supports the digitalisation of new policy applications and renewal premium payments, further driving the transformation toward paperless operations and digital innovation within the insurance industry.Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life, said, “CTF Life has always been customer-centric and forward-thinking, committed to delivering quality experiences and services to our customers. AlipayHK has a large base of active users in Hong Kong, and this collaboration fully leverages our synergies to provide customers with a more convenient, efficient, secure, and lifestyle-oriented payment experience. Moving forward, we will continue to create value beyond insurance by embracing innovative technologies and cross-sector collaborations to offer comprehensive support for customers at every stage of life.”Venetia Lee, CEO of AlipayHK, said, “AlipayHK is committed to collaborating with financial institutions to build a digital ecosystem, drive the digital upgrade of Hong Kong’s financial sector, and deliver more inclusive financial services to more citizens. Among AlipayHK’s over 4.5 million active users, one million are our wealth management users, which demonstrates public recognition of digital wealth management services. The partnership with CTF Life addresses users’ increasing wealth management needs by leveraging digital payment solutions to reshape the insurance application process, enabling users to manage and allocate their assets more efficiently.”CTF Life previously introduced the “ePay” feature on its mobile app, allowing customers to manage their accumulated policy value anytime and anywhere to enhance customer experience – a move that received positive feedback. This collaboration further enhances premium payment options, demonstrating the cross-industry synergy between CTF Life and AlipayHK. CTF Life will continue to harness resources from the Chow Tai Fook Group ecosystem to bring customers more convenient and lifestyle-oriented insurance products and services, accompanying customers throughput their life journey – from wellbeing, growth, and healthcare to legacy.* As of 15 December 2025Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life (right) and Venetia Lee, CEO of AlipayHK (left) jointly announce a collaboration that makes CTF Life’s mobile application the first among Hong Kong life insurers to enable premium payments via AlipayHK.About CTF LifeChow Tai Fook Life Insurance Company Limited (“CTF Life”) is proud of its rich, 40-year legacy in Hong Kong. CTF Life is a wholly-owned subsidiary of CTF Services Limited (“CTFS”) (Hong Kong Stock Code: 659) and one of the most well-established life insurance companies in Hong Kong. As a member of Chow Tai Fook Enterprises Limited, CTF Life consistently strengthens its collaboration with the Chow Tai Fook Group ecosystem to support customers and their loved ones in navigating life’s journey with personalised planning solutions, lifelong protection and diverse lifestyle experiences. By leveraging the Group’s robust financial strength and strategic investments across the globe, CTF Life aspires to become a leading insurance company in Asia while continuously creating value beyond insurance.About AlipayHKThe AlipayHK electronic wallet is operated by Alipay Financial Services (HK) Limited (Stored Value Facility Licence number: SVF0004) and regulated by the Hong Kong Monetary Authority. Currently, over 150,000 local retail outlets support AlipayHK electronic wallet for payments, covering large chain stores, shops, convenience stores, supermarkets, markets, and restaurants. Additionally, AlipayHK electronic wallet payment service also supports multiple overseas countries, including Chinese Mainland, Japan, South Korea, Thailand, Singapore, and Malaysia. For more details, please visit: http://www.alipayhk.com.Apart from payment services, AlipayHK also serves as a comprehensive digital lifestyle platform, offering Hong Kong users a wide range of lifestyle, leisure, and convenience services. Features include transportation, financial management, cross-border payments, P2P transfers, blockchain remittances, bill payments, purchasing insurance products offered by third parties, and receiving electronic vouchers. This allows Hong Kong citizens to enjoy the convenience brought by this revolutionary multifunctional electronic wallet. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BERLIN, Germany, Dec 16, 2025 - (ACN Newswire via SeaPRwire.com) - Market Logic Software, the market-leading SaaS provider of insight management solutions, has announced a partnership with Matter, a New Zealand-based intelligence company for brand builders and experience creators. This collaboration marks an exciting step in Market Logic's expansion across APAC, particularly in New Zealand and Australia, where Matter is working closely with local brands that want to deepen their customer and market understanding.Together, Market Logic and Matter will empower APAC businesses to uncover unique insights faster and take swifter action. By combining the power of Market Logic's AI-powered insights platform, DeepSights, with the data, research and measurement expertise of Matter, the two companies will help ambitious local brands drive international growth through intelligence."New Zealand and Australia are home to exceptional brands who are no strangers to innovation and creativity," said Oliver Allen. "By combining our strategic and creative intelligence with DeepSights' market leading AI capabilities, we're helping these teams accelerate confident decision-making. We believe the real magic happens when smart, industry leading technology is combined with deep research, cultural and insights expertise, and that's what we hope to deliver through this partnership.""Matter understands the unique dynamics of APAC brands and the consumers they serve," said Maarten Sambre, SVP Global Sales at Market Logic Software. "With DeepSights, we can support these organisations with verified insights at speed, while Matter ensures those insights translate into smart, creative brand and experience strategies."This partnership also represents a shared commitment to supporting APAC's rapidly evolving insights landscape, where the demand for AI-powered intelligence continues to accelerate. Market Logic and Matter will collaborate on brand engagements, regional activation campaigns, and thought leadership focused on smarter, insight-led decision making.For more information about the partnership, please contact:Daniela ZuinCMOMarket Logic Softwaredaniela.zuin@marketlogicsoftware.comTel: +44 7799 113040Oliver AllenPartnerMatteroliver.allen@matter.nzTel: +64 27 448 6008About Market Logic SoftwareMarket Logic is the leading SaaS provider of market intelligence and insights solutions. Powered by our special purpose AI for Insights technology DeepSights, our platform allows insights teams and business decisions makers to turn trusted insights into business impact at scale and speed. We've helped hundreds of consumer-focused brands across the globe to transform into insights-driven businesses. Market leaders such as Unilever, Vodafone, Bayer, and Tesco are driving innovation and making smarter market moves with the support of Market Logic. Find out more at https://marketlogicsoftware.com/.About MatterMatter is an intelligence company for brand builders and experience creators. We help organisations gain the clarity and confidence they need to make decisions that unleash commercial success. Blending strategic rigour with creative craft, we transform complex data into simple, powerful intelligence that drives brand and experience performance. Clients-from ambitious startups to global enterprises-choose Matter for our ability to deliver fast, impactful, and beautifully executed work.Find out more at https://www.matter.nz/SOURCE: Market Logic Software, GmbH Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

KUALA LUMPUR, December 16, 2025 - (ACN Newswire via SeaPRwire.com) – CBL International Limited (NASDAQ: BANL) (the "Company" or "CBL"), the listing vehicle of the Banle Group ("Banle" or "the Group") is proud to announce it has been awarded the prestigious EcoVadis Silver Medal, placing the company among the top 15% of organizations globally assessed for sustainability performance.The EcoVadis Silver Medal recognizes CBL's robust sustainability management system and comprehensive approach to corporate responsibility across four key dimensions: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. This achievement reflects the company's commitment to integrating sustainability into its core business operations and value chain."Earning the EcoVadis Silver Medal is a significant milestone that validates our ongoing dedication to responsible business practices," said Dr. Teck Lim Chia, Chairman and CEO of Banle Group. "At CBL, sustainability isn't an add-on—it's embedded in how we operate daily. This recognition reflects our team's collective efforts to build a business that delivers both commercial success and positive societal impact."The EcoVadis assessment, which analyzes companies' sustainability management systems based on international standards including the UN Global Compact, ISO 26000, and ILO conventions, places CBL in the 85th percentile or higher globally. To qualify for the Silver Medal, CBL demonstrated strong performance across all sustainability themes, meeting rigorous minimum score requirements in each category.This achievement comes as CBL continues to advance its sustainability initiatives, including its commitment to maritime decarbonization through biofuel distribution and next-generation fuel development. The company has recently reported a 154.7% year-on-year surge in biofuel sales in the first half of 2025, demonstrating how environmental stewardship and business growth can go hand in hand.CBL's sustainability journey includes measurable carbon reduction targets, ethical supply chain governance, community investment programs, and transparent ESG reporting. The company's recent recognition with the "Excellent Sustainability Award" at the CGMA Annual Awards 2025 and "Directors of the Year Awards – Listed Companies Executive Directors category - Dr. Teck Lim Chia" presented by the Hong Kong Institute of Directors (HKIoD) further underscores its leadership position in sustainable maritime logistics.The company remains committed to advancing its sustainability performance, with plans to further strengthen its environmental initiatives, enhance social impact programs, and deepen governance frameworks in alignment with global best practices. Caption: CBL INTERNATIONAL LTD has been awarded the EcoVadis Silver Medal, a recognition granted to the top 15% of organizations globally assessed for sustainability performance by EcoVadis within the 12 months preceding the medal award date.About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications.For more information about our Company, please visit our website at: https://www.banle-intl.com. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, December 15, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX: 1952.HK) today unveiled its 2030 strategy. Following the announcement, the Company’s shares strengthened during the trading session and briefly reached an intraday high of HKD 48.54. By market close, the stock was trading at HKD 46.88, with the share price remaining at relatively elevated levels throughout the session, representing a gain of 4.55%, indicating a positive market response.According to market commentary, the strong performance on the day reflected both investor focus on the Company’s newly articulated medium- to long-term strategy and confidence signals released earlier by Directors and substantial shareholder. Previously, the Company also announced that certain Directors and a substantial shareholder have increased their shareholdings in the Company. On December 12, 2025, Mr. Wei Fu, Non-executive Director, Honorary Chairman of the Board and a substantial shareholder of the Company; Mr. Yifang Wu, Executive Director and Chairman of the Board; Mr. Rogers Yongqing Luo, Executive Director and Chief Executive Officer; and Mr. Ian Ying Woo, Executive Director, President and Chief Financial Officer, collectively acquired 846,659 ordinary shares of the Company through open-market transactions, for a total consideration exceeding HK$38 million, representing an average price of approximately HK$45.01 per Share. In addition, the Company has been informed that CBC Group, a substantial shareholder of the Company, has further undertaken that it plans to increase its shareholding by not more than 1% in aggregate in the following three to six months, subject to the market conditions and compliance with applicable laws and regulatory requirements. The relevant actions are seen as a clear indication of Directors and substantial shareholders' positive stance on the company's long-term development prospects.The Company's 2030 strategy sets out a dual-engine approach to deliver predictable near-term growth and value creation through commercialization of existing assets, business development partnerships, and in-house R&D milestones, while driving long-term growth and value creation through in-house R&D and discovery, as well as global commercial expansion. Everest Medicines will continue to strengthen its leadership in core therapeutic areas, advance the development and commercialization of innovative therapies, and build a globally competitive biopharmaceutical company with sustainable growth.Everest Medicines focuses on renal, autoimmune, critical care, cardiovascular, and ophthalmic disease area, advancing its pipeline through a combination of in-licensed innovative assets and in-house R&D. By 2030, the Company aims to build a high-value commercial product portfolio while selectively expanding into additional valuable therapeutic areas with blockbuster potential.The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle. By 2030, Everest Medicines targets annual revenue exceeding RMB 15 billion, including approximately RMB 9 billion from its existing pipeline and RMB 6 billion from newly in-licensed assets, while also exploring potential out-licensing opportunities. Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafter. Over the same period, the number of commercial products is expected to exceed 20, including NEFECON®, Velsipity®, XERAVA®, cefepime–taniborbactam, and Lerodalcibep.To support its international growth, Everest Medicines is advancing a global strategy focused on strengthening regulatory and clinical development capabilities, while progressively building commercial infrastructure across Europe, the United States, and emerging markets. By 2030, the Company aims to drive growth through a combination of overseas out-licensing and direct commercialization, accelerating its global expansion.Notably, as a major shareholder of NovaBridge Biosciences, holding approximately 16% of its issued share capital, the Company will collaborate with NovaBridge Biosciences to identify high-quality assets and enhance global R&D and commercialization capabilities through complementary strengths and resources."The 2030 Strategy reflects Everest Medicines' clear vision for commercialization, R&D, and global expansion, and reinforces the Company's ability to deliver sustainable value. Since its founding in 2017, the Company has built a strong foundation through in-licensing innovative assets, completing its IPO, and executing a dual-engine strategy focused on high-potential therapeutic areas and strong commercialization and R&D capabilities," said Mr. Wei Fu, Honorary Chairman of the Board of Everest Medicines and CEO of CBC Group. "CBC Group will continue to leverage its global resources and ecosystem to support the Company's growth, spanning pipeline advancement, platform building, and organizational expansion. The recent share purchases by the Directors and CBC Group's announced intention to increase its shareholding further demonstrate strong confidence in Everest Medicines' long-term prospects.""The 2030 Strategy marks a key milestone for Everest Medicines, guiding growth through BD partnerships and in-house R&D to build a larger commercial portfolio and pursue new high-potential blockbuster opportunities. Leveraging its BD capabilities and the CBC ecosystem, the Company plans to add three-to-five late-stage, high-value assets annually, aiming for peak sales within three years of reimbursement, with more than 20 new assets expected to contribute around RMB 6 billion by 2030 and RMB 30 billion by 2035. Our strong balance sheet and cash flow from commercial activities will support the implementation of our strategic initiatives." said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "We will also continue to advance our in-house R&D platforms and, through our collaboration with Hasten, strengthen the late-stage pipeline and market reach.""Everest has established a scalable commercialization platform integrating medical, access, marketing, and sales capabilities," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "As a chronic disease therapy, NEFECON® generated over RMB 1 billion in sales during the first three quarters of its first full year following commercial launch, validating our commercial effectiveness. Building on this success, we will extend our commercial model and expertise from renal and anti-infective therapies to additional therapeutic areas, while advancing our in vivo mRNA CAR-T and mRNA tumor vaccine platforms, addressing unmet medical needs in China and globally."Overall, the release of Everest Medicines' 2030 strategy not only sets out a systematic roadmap for future business development but also, through proactive share purchases by Directors and substantial shareholder, reflects aligned internal and external confidence in the Company's long-term prospects. Looking ahead, guided by its dual-engine strategy, Everest Medicines aims to strengthen its position in core therapeutic areas and innovative drug R&D, while building a globally competitive biopharmaceutical company with sustainable growth. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - December 15, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide the latest progress update on the Graphene Aluminium-Ion Battery technology ("G+AI") being developed by GMG and the University of Queensland ("UQ") under a Joint Development Agreement with Rio Tinto, one of the world's largest metals and mining groups, and with the support of the Battery Innovation Center of Indiana ("BIC") in the United States of America.Based on its current state of development as reflected below, the GMG G+AI Battery has similar performance characteristics to those provided by High Power Lithium Titanate Oxide ("LTO") batteries, which are sold at a premium price of up to US$1500/kWh. However, the GMG G+AI Battery can be produced at a substantially lower cost and therefore can be priced below that of LTO batteries. In 2025, sales of LTO batteries, which are used in many applications globally, totalled US$ 5.6[1] billion.Battery Performance Update:GMG is pleased to announce that it has progressed its G+AI Battery technology and believes that, once development is completed, it can meet the key target specification requirements for the main targeted battery use case as per Figure 1, including:Charging in under 6 minutes;Energy density > 100 Wh/kg after 1 hour of charging;Long Cycle Life (10,000 cycles);Safe (no Lithium);Lower Thermal Runaway Risk; andLikely no thermal management system will be needed.Bob Galyen, GMG Non-Executive Director, commented: "In my nearly five decades in the battery industry, I have rarely seen a technology with the disruptive potential of GMG's next-generation graphene aluminium-ion battery. With the possibility of charging from empty to full in around six minutes, this chemistry fundamentally changes how designers can think about electric vehicles, consumer electronics, and stationary storage. Instead of planning around long charge stops with large packs, engineers can optimise for rapid energy turnaround, with higher power, and safer, with GMG's battery made from abundant raw materials. Lithium-ion will remain a key part of the energy landscape for years to come, but its limitations in fast charging, temperature tolerance, and critical-mineral supply are increasingly evident. By leveraging aluminium and graphene, the GMG team is demonstrating a pathway to reduce reliance on traditional lithium-based systems while delivering step-change improvements in charge time and power density. This is not an incremental tweak to existing cells - it is a new platform that can open markets and use cases that were previously uneconomic or impractical. As GMG moves from the lab toward scaled manufacturing, its primary focus is on proving reliability, safety, and cost at industrial level. Automotive, grid, and specialty-device partners are already engaging with GMG to explore pilot programs and early integrations. The companies that adapt quickest to this shift will lead the next wave of electrification, and GMG intends to be at the centre of that transition with graphene aluminium-ion technology."Figure 1: G+AI Battery Use Case - heavy mobile equipmentTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_gmg_figure1.jpgGMG is pleased to share the energy densities of the current GMG G+AI pouch cell at 60 minutes and 6-minute charging compared to other chemistry batteries on the market (Figure 2), and a voltage vs capacity graph (Figure 3) of its latest G+AI Battery technology based on data provided by the third-party BIC battery testing laboratory.Based on that testing, the current stage of development, batteries produced by GMG and BIC had an energy density of 58 Wh/kg when charged in 1 hour and 26 Wh/kg when charged in 6 minutes. In 6-minute fast charging, the battery cells achieved 62% capacity in 3.2 minutes. The batteries had a nominal voltage of approximately 3.0 Volts and maintained performance over hundreds of cycles at 6-minute fast charging, without the significant degradation typically observed in lithium and sodium-ion batteries at such high charging rates.Figure 2: Different Battery Chemistry Performance at 6 min and 60 min Charge[2]To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_002full.jpgStandard commercial Lithium Nickel Manganese Cobalt ("LNMC") and Lithium Iron Phosphate ("LFP") battery cells for electric vehicles and stationary storage are not designed for continuous 6-minute charging (10C); typical recommended charge rates are ≤1 hour (1C), often 2 hours (0.5C), with only limited fast charge operation. Only specialized high-power cell designs like LTO battery cells can tolerate charge rates of 6 minutes (10C).[3]Figure 3: Battery performance curves of GMG's G+AI Battery at 60 min and 6min chargeTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_003full.jpgGMG has now developed a completely new hybrid electrolyte that is chloride free and noncorrosive, unlike common aluminium battery electrolytes, along with a complex cathode and anode technology that enables very stable fast charging over several cycles. The substrate for both the cathode and anode in the GMG G+AI Battery is aluminium foil - which provides significant cost and weight savings compared with copper, the substrate material used in most lithium and sodium-ion batteries. GMG's technology does not include the use of lithium or copper. The Company has submitted an additional patent application covering these new developments.Craig Nicol, GMG Managing Director and CEO, commented: "I couldn't be happier with the GMG team to get to this point with our battery. We have rebuilt this battery in our weekly sprints from the ground up and developed completely new complex cathode, anode and electrolyte. This will provide a next generation fast charging battery technology currently not available in the world, and we look forward to sending out sample cells to test with partners in early 2026. This technology has many years of development in front of it and will improve as we keep pushing through known issues to improve capacity, voltage and reduce weight."GMG management believes that the Company's battery technology can eventually achieve over 150 Wh/kg when charged in 1 hour, and over 75 Wh/kg when charged in 6 minutes. The Company believes further development of the cathode, anode, electrolyte and component weights will eventually achieve this end goal.Figure 4 shows the latest Graphene Aluminium-Ion Battery multi-layer pouch cell.Figure 4: Current Multi-Layer Battery Pouch CellTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_004full.jpgBattery Technology Readiness LevelThe battery technology readiness level ("BTRL") of the G+AI technology remains at Level 4, see Figure 5. GMG is currently optimizing electrochemical behaviour for pouch cells via ongoing laboratory experimentation. Through collaboration with BIC, it is anticipated that the battery technology readiness will progress to BTRL 7 and 8 since the equipment and processes needed to produce the G+AI batteries are the same as those employed to make Lithium-Ion Batteries.Figure 5: Battery Technology Readiness Level (BTRL)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_005full.jpgThe Company is confident it can meet the overall timeline, as seen in Figure 6, of its battery cell roadmap that calls for testing of cells with customers in 2026 and small commercial production with support of various partners, including BIC, in 2027.Figure 6: Battery Cell RoadmapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_006full.jpgNext Steps Toward Commercialisation & Market ApplicationsJack Perkowski, GMG Chairman and Non-Executive Director, commented: "I am extremely proud that GMG has progressed its battery to this stage. It is a significant milestone for the Company because the battery technology has so much opportunity in so many applications - especially in commercial vehicles. I look forward to the next updates as GMG makes further progress in the development of its battery technology."The Company continues to see a broad range of applications for a completed GMG G+AI Battery - utilising its ultra-high power-density and economic energy density characteristics. Along with Rio Tinto, a range of global companies have confidentially expressed their interest in working with GMG in the following vertical sectors:Figure 7: Market ApplicationsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_007full.jpgCurrently, GMG believes it will use a plastic battery pack design, similar to Figure 8, to hold the battery pouch cells - reducing the weight, cost and complexity of using a metal case. Using a plastic battery pack is possible for two main reasons - GMG believes that its battery will not require a thermal management system or the fireproofing precautions provided by the metal case in a lithium-ion battery. Using plastic will increase the comparative energy density of GMG's G+AI battery packs when compared to lithium-ion batteries.Figure 8: Expected Battery Pack for G+AIB Pouch CellsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_008full.jpgComparison and Market Review: LTO Batteries As shown in Figure 9 below, the performance of GMG's G+AI battery technology is already very similar to LTO batteries.Figure 9: Comparison of Graphene Aluminium-Ion Battery (G+AI) to Lithium Titanate Oxide (LTO) BatteryParameterHigh Power LTO[4]GMG G+AI BatteryRapid Charging80% in 6 minutes100% in 6 minutesEnergy Density - 6-minute charge37 Wh/kg (80% of Capacity)46 Wh/kg (6 min +)26 Wh/kg(Current)Large upside to be confirmedDepth of DischargeFull RangeFull RangeSafetySafeSafer (no lithium fire potential)Longevity70% performance over 20,000 cyclesTo be confirmedBattery PriceUS$800 - US$1500 / kWh[5]Lower price due to lower material costsNo lithium, no TitaniumMarket SizeUS$5.6 Billion in Sales in 2025Under development LTO batteries are sold at a premium to LFP and LNMC batteries, which are the main chemistries used in electric vehicles and energy storage systems, and are also widely used in other electronic applications due to their high performance and long cycle life. The material and manufacturing costs for GMG's G+AI Battery are expected to be similar to, or less than, the cost to manufacture standard lithium-ion batteries, but substantially lower than the costs to produce LTO batteries.LTO batteries have energy density ranging from 50 - 80 Wh/kg.[6] The LTO product is sold globally for use in many applications - with a total of US$5.6[7] billion sales per annum in 2025. Sales of LTO batteries are expected to grow at 10% per annum to an estimated US$ 9.0 billion by 2030. The major manufacturers of LTO batteries include Toshiba, Gree, Microvast and CATL.Further details on applications for the LTO battery from Mordor Intelligence7 are described below. In many of the use cases for LTO batteries, GMG believes that its G+AI Battery can be substituted at a substantially lower cost.Commercial Vehicles: Automotive, primarily buses, refuse trucks, and drayage tractors rather than passenger cars, is the largest user of LTO batteries. Fleets realize five-year total-cost-of-ownership parity once fuel savings and lower maintenance offset higher upfront prices.Fast-charging Electric Buses and Trucks: Transit authorities need battery systems that accept repeated high-power "opportunity charges" during short layovers. LTO cells replenish 80% capacity in roughly five minutes, allowing operators to shrink fleet size without sacrificing route frequency. U.S. Low-No Emission Bus grants earmark more than US$1.5 billion per year, with bid specifications that explicitly reference rapid-charge capability. Parallel subsidy programs in China reimburse up to CNY 80,000 (US$ 11,396) per new-energy bus, accelerating volume deployment in provincial capitals.Hybrid and BEV: Regenerative braking and high-C-rate acceleration favour the use of LTO batteries. Use in fast-charge EV stations is growing rapidly as ride-hailing fleets adopt swap-ready models.Stationary Storage: Utility-scale batteries now cycle multiple times per day for frequency regulation, peak shaving, and voltage support. Energy-storage-system integrators adopt LTO batteries for grid-frequency response where state-of-charge swings are shallow but frequent.Industrial Robotics: LTO batteries are used in continuous-duty forklifts that require partial charges during operator breaks.Aerospace and Defense: Unmanned aerial vehicles, missile auxiliaries, and soldier-worn power banks operating from -40 °C to +60 °C ambient.5-minute Battery-Swap Stations: Battery-as-a-service platforms require ultra-fast turnaround and high cycle life. CATL confirmed plans to install 1,000 swap stations in 2025 and 30,000-40,000 by 2030, each requiring packs that tolerate thousands of rapid exchanges without degradation.Sub-10 kWh Packs: Cordless construction tools, autonomous ground vehicles, and medical carts select LTO batteries to bypass daily pack swaps.12V starter replacement to Lead acid: GMG's G+AI battery technology would be a viable 12 V starter-battery replacement for lead-acid, offering lower weight, longer cycle life, good low-temperature performance and improved cold-cranking capability, together with excellent tolerance to storage at 0% state of charge. In suitable system designs, the chemistry's stable voltage behaviour can also reduce balancing requirements and simplify battery management, helping to lower overall system cost.Lifecycle Procurement Preference: Many government procurement frameworks now weigh lifecycle reliability higher than purchase price. For example, New Mexico awarded a US$ 400 million bus electrification contract that included stringent thermal-runaway resistance metrics. Europe's Clean Industrial Deal allocates capital for storage technologies that stabilize renewables, aligning well with LTO batteries' fast-response profile.Cylindrical Cells: accounted for 37.7% of LTO battery sales in 2024 as entrenched production lines and robust steel casings satisfied heavy-duty demand. Pouch designs address aerospace weight requirements and constrained dashboards in autonomous robots.Summary of Important Milestones for GMG's G+AI Battery Development: MonthImportant Milestones in the Development of the Graphene Aluminium Ion BatteryMay 2020GMG and UQ win Australian Research Council grant for Graphene battery developmenthttps://graphenemg.com/gmg-and-uq-wins-australian-research-council-grant-for-graphene-aluminium-ion-battery-development/ Apr 2021The University of Queensland and GMG kick off coin cell battery development projecthttps://graphenemg.com/gmg-the-university-of-queensland-research-uni-quest-kick-off-the-graphene-enhanced-aluminium-ion-battery-development-project/May 2021Graphene aluminium-ion battery performance data - Energy Density and Power Densityhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-performance-data/Jun 2021Graphene aluminium-ion battery performance data - Cycle Lifehttps://graphenemg.com/graphene-aluminium-ion-battery-performance-data/Jun 2021Significant potential battery customer market response to launch of batteryhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-progress-update/Jul 2021Investment decision for coin cell battery development centrehttps://graphenemg.com/gmg-battery-pilot-plant-investment/Oct 2021Construction starts for coin cell battery development centrehttps://graphenemg.com/construction-battery-pilotplant/Oct 2021Bosch Australia Manufacturing Solutions and GMG sign Letter of Intenthttps://graphenemg.com/gmg-and-bosch-sign-collaboration-arrangement-for-bosch-to-design-and-deliver-gmgs-graphene-aluminium-ion-battery-manufacturing-plant/Dec 2021Commencement coin cell battery development centrehttps://graphenemg.com/battery-pilot-plant/Dec 2021Initial coin cell batteries sent for customer feedbackhttps://graphenemg.com/graphene-aluminium-battery-customers-prototypes/Mar 2022Initial factory acceptance testing of semi-automated prototype battery cell assembly equipmenthttps://graphenemg.com/gmg-announces-initial-factory-acceptance-testing-of-semi-automated-prototype-battery-cell-assembly-equipment/Mar 2022Wood Engineering and GMG Sign a Letter of Intenthttps://graphenemg.com/gmg-and-wood-agree-collaboration-arrangement-for-wood-to-engineer-and-deliver-major-graphene-manufacturing-expansion-projects/May 2022Rio Tinto and GMG sign Letter of Intenthttps://graphenemg.com/gmg-riotinto-energysavings-battery/Jun 2022Commissioning of Pouch Cell Equipmenthttps://graphenemg.com/gmg-manufactures-first-pouch-cell/Jun 2022Bob Galyen, former chief technology officer of CATL, joins GMG technical advisory committee.https://graphenemg.com/gmg-technical-advisory-committee-leadership-team-additions-and-cfo-change/Aug 2022Investment decision for Phase 1 modular Graphene Production Planthttps://graphenemg.com/gmg-announces-phase-1-expansion-project-to-graphene-manufacturing-facility-for-energy-saving-products-and-batteries/Oct 2022Significant battery performance, cell and graphene production improvementshttps://graphenemg.com/gmgs-battery-update-significant-battery-performance-cell-and-graphene-production-improvements/Dec 2022Investment of $600k Battery Development Centrehttps://graphenemg.com/gmg-invests-au-600000-to-accelerate-battery-pouch-cell-customer-testing-development-in-2023/Feb 2023Australian Government Approval (AICIS) for production and sale of batteries.https://graphenemg.com/gmg-receives-regulatory-approval-to-enable-significant-commercial-sales/May 2023Battery Joint Development Agreement with Rio Tinto signedhttps://graphenemg.com/gmg-announces-battery-joint-development-agreement-with-rio-tinto/May 2023Battery Technology Readiness Level (BRTL) 2-3 reachedhttps://graphenemg.com/gmg-announces-battery-team-and-related-updates/May 2023Decision to switch to develop Pouch Cells (instead of Coin Cells)https://graphenemg.com/gmg-announces-battery-team-and-related-updates/Jul 2023Bob Galyen former chief technology officer of CATL joins GMG board of Directorshttps://graphenemg.com/graphene-manufacturing-group-appoints-former-chief-technology-officer-of-catl-limited-to-its-board-of-directors/Sep 2023Battery Pouch Cell Prototypes Multilayered Auto-Stacker Demonstrationhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-pouch-cell-prototypes-multilayered-auto-stacker-demonstration/Sep 2023Reaching 500 mAh capacity batteryhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Sep 2023Battery Technology Readiness Level (BRTL) 4 reachedhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Nov 2023Rio Tinto and GMG Partnership Video Launchedhttps://graphenemg.com/rio-tinto-gmg-battery-partnership-video-launch/Dec 2023Commissioning of modular Graphene Production Planthttps://graphenemg.com/graphene-manufacturing-group-commissions-modular-graphene-production-plant/Feb 20241000 mAh Capacity Reachedhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-1000-mah-capacity-reached-and-next-steps-toward-commercialisation/Mar 2024Graphene Manufacturing Group Secures AU$2 million Funding Grant from Queensland Government for Battery Pilot Planthttps://graphenemg.com/graphene-manufacturing-group-secures-au2-million-funding-grant-from-queensland-government-for-battery-pilot-plant/Aug 2024GMG's Graphene Aluminium-Ion Battery: Progress Update and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-progress-update-and-next-steps-toward-commercialisation/Mar 2025GMG's Graphene Aluminium-Ion Battery: Collaboration with World Leading USA Battery Innovation Centre and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-collaboration-with-world-leading-usa-battery-innovation-centre-and-next-steps-toward-commercialisation/ About BIC:BIC is a collaborative initiative designed to incorporate leadership from renowned universities, government agencies, and commercial enterprises. BIC is a public-private partnership and a not-for-profit organization focusing on the rapid development, testing and commercialization of safe, reliable and lightweight energy storage systems for defense and commercial customers. BIC is a unique organization that has been leading battery cell development for world leading battery companies for over 10 years and has carried out over 500 battery development projects.About GMGGMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041www.graphenemg.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the lower cost to produce GMG G+AI batteries, expectations for GMG G+AI batteries in respect of charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system when development is completed, that the new hybrid electrolyte is chloride free and non-corrosive, that the cathode and anode technology employed enables very fast and stable charging, that GMG G+AI batteries provide significant cost and weight savings relative to copper, that G+AI batteries can achieve over 150 Wh/kg charged over 1 hour and 75 Wh/kg when charged over 6 minutes following further development of cathode, anode, electrolyte and component weights, that G+AI batteries will progress to BTRL 7 and 8, that the timeline for the battery cell roadmap is achievable, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and which offers weight, cost and complexity advantages to a metal case and increased energy density, expectations for the lack of a thermal management system or fireproofing precautions, expectations for material and manufacturing costs, expectations for sales of LTO batteries, expectations for G+AI batteries being substitutable for LTO batteries at lower cost, expectations that G+AI batteries are viable 12V starter battery replacements and the rationale therefor and the advantages of pouch design for aerospace weight requirements and constrained dashboards of autonomous robots.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions that GMG G+AI batteries can be produced at lower cost, as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries, the speed and stability of charging, that G+AI batteries will progress to BTRL 7 and 8, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and offer weight, cost and complexity advantages to a metal case and increased energy density, that the service agreement with the BIC will enable the Company to optimize its cell design and battery manufacturing equipment, and that the Company will be able to meet its overall timeline on the battery cell roadmap. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that GMG G+AI batteries cannot be produced at lower cost, or any of the assumptions as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries can not be achieved, G+AI batteries do not offer expected speed and stability of charging, that G+AI batteries will not progress to BTRL 7 and 8, that a range of global companies in a variety of industries will not be interested in working with GMG, that the battery pack design will not be plastic and not offer weight, cost and complexity advantages to a metal case and increased energy density, that the Company will not be able to optimize the electrochemical behaviour of the pouch cell through laboratory experimentation or at all, that the Company will not be able to meet its overall timeline on the battery cell roadmap, that the service agreement with the BIC will not enable the Company to optimize its cell design and battery manufacturing equipment and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 04, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.[1] Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends Report[2] LFP: https://www.evlithium.com/catl-battery-cell/catl-150ah-lifepo4-battery-cell.htmlLNMC: https://keheng-battery.com/product/catl-nmc-3-7v-151ah-high-energy-density-battery-for-ev/LTO: https://www.global.toshiba/ww/products-solutions/battery/scib/product-next/product/cell/high-power.htmlLead Acid: https://www.altronics.com.au/p/s4530-12v-3.5ah-sealed-lead-acid-sla-battery/?srsltid=AfmBOoqZGMEIsX__YYOuRLC3nvYDFtNkf35qZYuYeoh3ACf4wrrOLISD[3] https://findingspress.org/article/21459-impact-of-charging-rates-on-electric-vehicle-batt[4] High-power type cells | SCiB™ Rechargeable battery | Toshiba[5] https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.[6] https://www.grepow.com/blog/battery-energy-density.html[7] Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends ReportTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/278044 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing.In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile[1]. In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future.Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo.The Product's inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options.The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries).About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-data-phase-2b-study-evaluating-povorcitinib2. Datas are from the China Insights Consultancy (CIC) reportCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

JAKARTA, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - Indonesia's state-owned railway operator PT Kereta Api Indonesia (KAI) has rolled out two major initiatives aimed at strengthening national mobility and accelerating its digital shift: the launch of the Farmer and Trader Train on the Merak Commuter Line, and the expansion of face recognition boarding technology ahead of the 2025/2026 Christmas and New Year travel season.Farmer-Trader train to facilitate the movement of agricultural goods, processed food, and small-scale merchandise by providing dedicated cargo space within a commuter railway environment.KAI said the programs reflect its commitment to inclusive transport services while enhancing operational efficiency and environmental performance — moves that align with international railway modernization trends.A special passenger train featuring oversized windows and often a large glass roof (sunroof) to provide unobstructed, wide-angle views of the passing scenery, turning the journey itself into a scenic experience."KAI is committed to building a rail ecosystem that supports grassroots economies while adopting technologies that meet global service standards," said KAI President Director Bobby Rasyidin. "These initiatives reinforce railways as an inclusive, efficient, and sustainable mode of public transport."New Farmer–Trader Train Strengthens Local Product DistributionEffective 1 December 2025, KAI began operating the Farmer and Trader Train on the Merak–Rangkasbitung corridor in Banten Province. The service is designed to facilitate the movement of agricultural goods, processed food, and small-scale merchandise by providing dedicated cargo space within a commuter railway environment.The rolling stock was fully redesigned by Balai Yasa Surabaya Gubeng, KAI's technical workshop, which modified the interior layout, baggage sections, loading–unloading access points, and safety signage to meet the needs of micro and small enterprises."The train has been engineered by our in-house experts to ensure safe, orderly, and convenient goods movement without disrupting passenger flow," continued Rasyidin.The service operates under a government-funded Public Service Obligation (PSO) scheme with a flat fare of Rp3,000, allowing up to two cargo units per user. It is attached to 14 daily Commuter Line services and stops at 11 stations across coastal and agricultural areas.On launch day, 95 customers used the service, carrying agricultural produce, snacks, and handicrafts for markets in Serang, Cilegon, and Merak. KAI expects the service to reduce traders' reliance on road-based logistics and shift more local supply chains onto rail.Rasyidin said the initiative strengthens regional economic resilience: "Reliable logistics access for small producers is fundamental to local economies. This service opens a more predictable distribution channel for farmers and traders."Facial Recognition Technology Boosts Efficiency, Cuts WasteKAI is also expanding its facial recognition boarding system to improve passenger processing and reduce paper usage in major stations.KAI VP Public Relations Anne Purba, explains, between January and October 2025, the feature recorded 9.29 million uses, cutting ticket paper consumption by 23,245 rolls, equivalent to Rp341 million in savings. Since the system debuted in 2023, it has been used by 19.4 million passengers, contributing significantly to KAI's environmental and cost-reduction goals."Facial recognition shortens boarding time and significantly reduces paper waste, supporting more environmentally responsible operations," Purba said.The technology is now available in 22 stations, with wider deployment planned ahead of peak holiday travel to reduce queues and streamline passenger flow.Purba underscored the strategic value of automation: "Digitalization is not just innovation—it is increasingly essential to managing national mobility at scale. This system helps maintain operational stability when travel demand peaks."Holiday Ticket Sales Climb, Discounts ExpandedDemand for the year-end holiday period—18 December 2025 to 4 January 2026—continues to rise. As of 26 November, KAI had sold 629,060 tickets, or 21.15% of the roughly 3 million seats available.To support affordability and smooth travel, KAI is offering 30% discounts for 156 regular services and 26 additional economy-class trains, totaling 1.5 million discounted seats valid from 22 December to 10 January.Purba said higher mobility is expected across Java and Sumatra: "We are preparing large capacity and fare incentives to ensure safe, orderly, and accessible travel throughout the holiday season."Inclusive and Technology-Driven Mobility for IndonesiaBy combining inclusive rural-focused services with large-scale digital transformation, KAI aims to bring Indonesia's rail sector closer to global standards of accessibility, efficiency, and sustainability."Our strategy aligns with international efforts to build modern public transport systems that deliver broad social and economic impact," Purba concluded.For More Information, please contact:Anne PurbaVP Public RelationsPT Kereta Api Indonesia (Persero)Source: PT Kereta Api Indonesia (Persero), https://www.kai.id Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TransNusa Launched 11 International Routes in 3 YearsIndonesia-based PT TransNusa Mandiri Aviation grows a strong brand with expansion focusing on international routesTransNusa focuses on international tourism island destinations to offer domestic and foreign tourists increased air connectivityTransNusa introduces four new domestic scheduled direct flights to boost connectivity from Bali to Lombok and Bima as well as between renowned diving destinations Manado to Sorong and Sorong to Timika, world’s largest gold mining islandJAKARTA, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - TransNusa has successfully launched four new domestic routes today, securing 19 routes in total within three years of operations.TransNusa Group CEO, aviation veteran, Datuk Bernard Francis, known for his acute, unique and out-of-the-box turnaround and change management strategies, led TransNusa towards a secure yet bold growth pattern using a customized business model, which was specifically developed to suit the changing market demand after the onslaught of the pandemic.“What we envisioned for TransNusa was to build an Indonesian-based airline with strong fundamentals. Today, thanks to our hard working and diligent team, the TransNusa brand has grown to resonates confidence and trust,” said Datuk Bernard, adding that TransNusa’s shareholder, China Aircraft Leasing Group Holdings Limited (CALC) and business partners also played a large role in helping build TransNusa into the strong brand it is today.Within 6 months of its operations, TransNusa launched its first international route between Jakarta and Kuala Lumpur, followed by three additional international routes in that same year, including Singapore and China.TransNusa also implemented a milestones as well as initiated and developed new domestic routes, such as the Bali-Manado route.In addition, TransNusa the first Indonesian airline to operate regular scheduled international flights into Guanzhou from three destinations in Indonesia.Datuk Bernard said the primary factor in the successful growth of TransNusa, in the last three years, was their goal to implement a lasting and impactful change around not just the organisation and its people but also its business model and operations.“In TransNusa, a 100% change is not possible overnight, whereas a 5% change in a moderate manner is not only more feasible but allows for a lasting change,” said Datuk Bernard, explaining that it was that principal which has been the backbone of TransNusa's operations and growth.On the new domestic route launches, Datuk Bernard said that TransNusa hopes to provide increased connectivity and travelling options to domestic and international tourists.“We would like to play our part in boosting and increasing air connectivity within Indonesia’s internationally renowned tourism island destinations.“Our focus is in increasing direct flight to destinations that are world renowned for its unique and stunning landscape and natural offerings,” said Datuk Bernard.DATUK BERNARD FRANCIS… TransNusa's team and business partners contributed to the growth of the airline and it’s brand.Flight DetailsTransNusa’s flight from Bali to Lombok will operate two times daily beginning Monday, December 15. The TransNusa flight will depart Bali from the Denpasar International Airport at 07.30am and arrive in Lombok International Airport at 07.55am, with the return flight departing Lombok at 08.25am and arriving in Bali at 09.05am. The second TransNusa flight will depart Bali at 15.55pm and arrive in Lombok at 16.50pm, with the return flight departing Lombok at 17.20pm and arriving in Bali at 18.05pm.“We will increase the frequency of the scheduled flights for the Bali-Lombok route to three times daily on December 21.” Said Datuk Bernard.The third scheduled flight will depart Bali at 18.55pm and arrive at Lombok at 19.35pm. The scheduled flight from Lombok will depart at 20.00pm and arrive in Bali at 20.25pm.Meanwhile, TransNusa’s flight from Bali to Bima will also begin on Monday, December 15.“For the first week, we will operate one scheduled flight from Bali to Bima on Monday, Wednesday, Friday and Sunday.“Starting December 22, TransNusa will operate daily scheduled flights from Bali to Bima,” said Datuk Bernard, adding that the flight will depart Bali from the Denpasar International Airport at 09.35am and arrive at 10.35am at the Sultan Muhammad Salahuddin Airport in Bima.The return flight will depart Bima’s Sultan Muhammad Salahuddin Airport at 11.00am and arrive at Bali’s Denpasar International Airport at 12.10pm.Meanwhile, TransNusa’s schedule flight from Sorong to Timika will operate four times weekly on Monday, Tuesday, Thursday and Saturday.The flight, which will also begin on December 15, will depart Sorong from the Domine Eduard Osok International Airport at 10.50am and arrive in Timika’s Mozes Kilangin Airport at 12.10pm. The return flight will depart Timika at 12.40pm and arrive in Sorong at 14.00pm.On the much sought-after Manado-Sorong route, Datuk Bernard said that TransNusa’s will operate its scheduled flight from Manado to Sorong four times weekly.The scheduled flight from diving haven Manado will operate on Monday, Tuesday, Thursday and Saturday. The flight will depart Manado’s Sam Ratulangi International AIrport at 08.00am and arrive in Sorong’s Domine Eduard Osok International Airport at 10.20am. The return flight will depart Sorong at 14.30pm and arrive in Manado at 14.50pm.TransNusa, A Short HistoryThe 3-year old TransNusa, led by aviation expert and veteran, Datuk Bernard, made waves in the aviation industry with its unique domestic and international business development and growth strategy.Within just 6 months of operations, in 2023, the airline, known then as a new player with new rules, launched its first international route between Jakarta and Kuala Lumpur, followed by the launch of scheduled flights between Jakarta and Singapore.TransNusa, which established itself as a Premium Service Carrier, made headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia to introduce new exciting routes. In 2023, during its first year of operations, TransNusa became the second Indonesian airline to receive approval to fly to China. In 2024, TransNusa became the first in the world to develop and introduce a new domestic route connecting Bali and Manado. In October 2025, TransNusa added yet another milestones by becoming the first Indonesian airline and second airline in the world to launch scheduled flights from Manado to Guangzhou, China.Media Contact:Trina Thomas RajMobile: +6012 4992672E-mail: trina@myqaseh.org Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Hong Kong’s exports are expected to grow by between 8% and 9% in 2026, according to figures releaased today by the Hong Kong Trade Development Council (HKTDC). The forecast forms part of the HKTDC’s annual Export Outlook report and follows on from the city’s better-than-anticipated 2025 export performance.For 2026, this sustained growth is set to be driven by robust demand for AI-related electronics products. According to the findings of the recently-released HKTDC 4Q25 Export Confidence Index, the majority of exporters (53.2%) see rising demand for AI/new technology-related electronic consumer goods as the factor most likely to boost their 2026 business. This is seen as crucial given that the electronics sector, overall, accounts for more than 70% of Hong Kong’s total export value.Heightened uncertainty giving way to greater clarityThese upbeat figures are remarkable given the high year-on-year comparison base from 2025. This is because many exporters sought to frontload orders in a bid to complete shipments before the imposition of the much-anticipated US tariffs.Detailing the upshot of the tariff-related trade upheavals in particular, Irina Fan, Director of HKTDC Research, said: “While 2025 proved to be a year of heightened uncertainty, 2026 should be a year of greater clarity on global trade. With the Chinese Mainland and the US having come to a trade agreement in November, – some four months after many other nations had struck their own deals with the Trump administration – US tariffs are no longer among Hong Kong exporters' three biggest 2026 concerns.”Fan did, however, acknowledge that uncertainties remain ahead. She said that as US imports from different countries are subject to different levels of tariffs, business leaders around the world will be looking to re-organise their activities to optimise any cost advantages.Outlining what this will mean within the Asia-Pacific region, Fan said: “Chinese Mainland exports to the US will be subject to 20% reciprocal tariff rate until November 2026 [1]. This comparatively low additional tariff puts China-based suppliers, many with more mature and highly productive supply chains, on par with their Southeast Asia counterparts, while giving them a significant advantage over any country subject to a higher tariff rate.”Multi-sector expectation of continued export expansionUnderpinning Hong Kong’s anticipated 2026 export expansion are the findings of the HKTDC Export Confidence Index 4Q25, which was also released today. The two key measures of this long-established quarterly metric –the Current Performance Index (51.4) and the Expectation Index (51.9) – have both stayed above the 50-point watershed level, a clear indication that future export growth is expected.Commenting on the findings of the 4Q25 survey, Kenneth Lee, Head of the HKTDC Research’s Special Project and Business Advisory Section, said: “When it comes to expansion plans over the next two-year period, Asia remains very much the focus. For 42.0% of respondents, the Chinese Mainland was the highest priority market, followed by the rest of Asia (30.3%) and the ASEAN bloc (18.9%). By industry, exporters in almost every sector saw scaling up their activities on the Chinese Mainland as their priority.”Beyond the headline findings of the survey, a more detailed analysis highlights good news for Hong Kong exporters in terms of both individual market prospects and the likely future success of most of the city’s key industry sectors.Positive sentiments for major markets and key industry sectorsIn specific terms, turning to the Market Expectation Sub-Index, the Chinese Mainland (57.2) and the ASEAN bloc (57.0) are still considered to have significant growth potential. Predictably, this was less the case for the US (down 1.4 to 38.0), with the uncertainties in its trade environment continuing to unsettle Hong Kong exporters.Turning to individual industries, a number of sectors have expansionary expectations for the year ahead (i.e. had a relevant index reading of 50 or more). Topping the list is Jewellery (54.8), followed by Electronics (52.4), Timepieces (51.6) and Equipment/Materials (51.1).Despite such overall positive sentiments, the survey also points out the possibility that a number of challenges may lie ahead. Most notably, it cited rising labour and production costs (53.9%), growing logistics challenges (38.8%) and declining overseas orders on account of the general economic slowdown (38.2%) as potential future concerns.[1] On top of Trump 1.0 tariffs of ~20% on averageReferencesHong Kong 2026 Export Outlook: Sustained AI Product Demand Set to Drive 8-9% Growth Over Coming Year:https://research.hktdc.com/en/article/MjE4ODc2Mzk2NwHKTDC Export Confidence Index 4Q25: End-of-Year Figures Indicate Positive Expansion Prospects:https://research.hktdc.com/en/article/MjE4ODYyNTQwNwHKTDC Research website: https://research.hktdc.com/en/ Photo download: https://bit.ly/4oJPrPRHKTDC Director of Research Irina Fan (right) and HKTDC Section Head, Special Project & Business Advisory, Kenneth Lee (left) announced the HKTDC Export Confidence Index for 2025’s fourth quarter at a press conference todayHKTDC Director of Research Irina FanHKTDC Section Head, Special Project & Business Advisory Kenneth LeeMedia enquiriesPlease contact the HKTDC’s Communication and Public Affairs Department:Navin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, December 12, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (“Everest Medicines China”), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. (“Hasten”). The first is a Commercialization Services Agreement leveraging Everest's existing sales and marketing organization to provide commercialization services for a portfolio of Hasten's mature assets.The second is a License Agreement granting Everest the exclusive license to develop, register and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor, which is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) in Greater China.The two agreements are expected to create significant financial and strategic synergies, enhancing the operational efficiency of Everest’s existing commercial platform and accelerating the build-out of life-cycle and multi-channel commercialization capabilities. At the same time, they establish an attractive strategic footprint for the Company in the cardiovascular disease area. Through this collaboration, Everest will further strengthen its commercial foundation in China, expand market share, and inject core momentum into the long-term growth of its cardiovascular business. The potential approval of Lerodalcibep in Greater China in 2027 is expected to contribute to future revenue growth within Everest's cardiovascular portfolio.Commercialization Synergies to Strengthen Competitiveness Across a Multi-Product PortfolioEverest Medicines China will receive service fees from Hasten calculated by multiplying the net sales of each product for the applicable quarter by the applicable rate, which ranges from 20% to 55%. The proposed maximum annual caps for the transactions contemplated to be paid by Hasten for the three years ending December 31, 2028 are set at RMB 560 million in 2026, RMB 616 million in 2027, and RMB 677 million in 2028.The Commercialization Service Agreement covers six mature, commercially available products across three major therapeutic areas—critical care, cardiovascular disease, and metabolic disorders—including Rocephin(R), Stilamin(R), and Ebrantil(R) in critical care; Edarbi(R) and Blopress(R) in cardiovascular disease; and Basen(R) in metabolic disease. The portfolio is highly synergistic with Everest’s existing commercial infrastructure and strategic focus. Among them, the three core critical care products—Rocephin(R), Stilamin(R), and Ebrantil(R)—play an essential clinical role in the treatment of infectious, gastrointestinal emergency, and cardiovascular emergency conditions. Rocephin(R), for example, is a broad-spectrum, third-generation cephalosporin that has achieved coverage in more than 8,500 hospitals nationwide and holds over 80% market share, maintaining strong and sustained clinical demand in the treatment of complex infections. Notably, these transactions are expected to generate significant synergies for Everest by aligning XERAVA(R) with Hasten’s critical care portfolio — including Rocephin(R) and Stilamin(R) — across complementary geographic footprints, channel access and hospital coverage, while further strengthening the Company’s commercialization capabilities and life-cycle management of innovative medicines.With the addition of this product portfolio, the Company’s commercial presence in key therapeutic areas such as critical care and cardiovascular diseases will be further expanded, creating stronger synergies with its existing commercialization organization and providing more robust support for the scaled development and revenue growth of its commercial platform.Introduction of Lerodalcibep to Expand Strategic Footprint in Cardiovascular DiseasesThe agreement grants Everest the exclusive license to develop, register and commercialize Lerodalcibep in Greater China, together with a royalty-free, exclusive license to use Hasten's trademarks for the product in the territory. Pursuant to the license agreement, Everest Medicines China will make an initial payment of US$29 million (approximately RMB 205 million), and may pay up to US$30 million (RMB 212 million) in potential development and regulatory milestone payments and up to US$280 million (RMB1977 million) in potential sales milestones, in addition to royalties based on the total, aggregate annual net sales.Lerodalcibep, developed by privately-held and U.S.-based company LIB Therapeutics, is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is a novel, small protein-binding, third-generation PCSK9 inhibitor, and has been developed as a more patient friendly and convenient, once-monthly, single small-volume, subcutaneous injection that will not require refrigeration at home or in travel. These features make Lerodalcibep a unique alternative to approved PCSK9 inhibitors. In large, global phase 3 clinical trials in over 2,500 patients, Lerodalcibep has demonstrated sustained LDL-C reductions of >60% in patients with, or at very-high or high risk of, cardiovascular disease (CVD) and >55% in those with heterozygous familial hypercholesterolemia (FH) who have more severe LDL-C elevations. In addition, the head-to-head LIBerate-VI study, comparing Lerodalcibep with Inclisiran, demonstrated the superiority of Lerodalcibep (p=0.0319). Lerodalcibep is expected to expand treatment options for the millions of patients around the world with CVD, including the 30 million individuals with FH. These LDL-C reductions have been confirmed in a recent phase 3 clinical trial in a Chinese population with, or at very high risk of, CVD including FH.Multiple PCSK9 inhibitors are currently approved and marketed in China, with a combined market size of approximately RMB 3 billion and year-over-year revenue growth of 95% in 2024. The market is expected to further increase to approximately RMB10 billion in 2030, according to a Frost & Sullivan report. Despite an estimated 400 million individuals in China with dyslipidemia, only ~14% receive lipid-lowering treatment, reflecting low penetration and significant unmet medical need. Lerodalcibep has patent exclusivity in China through 2039.Lerodalcibep is currently under regulatory review by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In Greater China, Biologics License Application (BLA) submission is expected in 1H 2026, with the potential for approval in 2027.Everest considers Lerodalcibep an important future growth driver and a key addition to its innovative medicines portfolio. The transaction is viewed as aligned with the Company’s strategy to focus on high-potential therapeutic areas and to expand its late-stage pipeline through business development collaborations, thereby strengthening its overall portfolio.Market commentators note that the two agreements provide both near-term revenue contribution and clear longer-term growth opportunities. By leveraging its established medical, market access, marketing and sales capabilities, Everest is expected to improve the efficiency of its commercial operations and resource utilization, while further demonstrating the scalability and resilience of its commercial platform. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com